Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Best Buy Co Inc (BBY) vs Boston Scientific Corporation (BSX) Price & Performance

Best Buy Co IncTrade
Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

Best Buy Co Inc vs Boston Scientific Corporation — how do they compare? Best Buy Co Inc trades at $83.6 (market cap $17.55B), while Boston Scientific Corporation trades at $51.59 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 4.2× Best Buy Co Inc's market cap, and Best Buy Co Inc pays a 4.61% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

BBYBSX
Market Cap
$17.55B$74.19B
Sector
Consumer CyclicalHealth
52-Week High
$90.17$108.14
52-Week Low
$55.52$42.63
Enterprise Value
$19.93B$86.27B
Dividend Yield
4.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Best Buy Co Inc

Best Buy (BBY) trades at $82.99, up 0.68% on the day, with a neutral technical outlook despite bullish moving averages. The company shows strong profitability with 39.1% ROE and 7.88% ROA, though revenue has declined from $51.8B in 2022 to $41.5B in 2025. Recent leadership changes include a new CFO appointment and marketing chief departure, while the company tests smaller store formats to drive growth.

The stock offers modest upside to the $84.31 consensus target with solid fundamentals but faces revenue pressure and leadership transition risks. Positive cash flow trends and consistent earnings beats support the investment case, though competitive retail pressures and macroeconomic headwinds remain concerns.

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX